Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | YF438 |
Synonyms | |
Therapy Description |
YF438 is an HDAC inhibitor, potentially inhibiting tumor growth and metastasis (PMID: 33985974). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
YF438 | YF-438|YF 438 | HDAC Inhibitor 45 | YF438 is an HDAC inhibitor, potentially inhibiting tumor growth and metastasis (PMID: 33985974). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MDM2 positive | triple-receptor negative breast cancer | sensitive | YF438 | Preclinical | Actionable | In a preclinical study, YF438 treatment inhibited H3 and H4 acetylation, promoted Mdm2 degradation, led to growth inhibition and increased apoptosis in triple-negative breast cancer cell lines in culture, and reduced tumor growth and metastasis, extended overall survival in an orthotopic autograft model (PMID: 33985974). | 33985974 |
MDM2 C464A | triple-receptor negative breast cancer | no benefit | YF438 | Preclinical - Cell culture | Actionable | In a preclinical study, YF438 treatment did not inhibit cell growth or induce apoptosis in triple-negative breast cancer cells expressing MDM2 C464A in culture (PMID: 33985974). | 33985974 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|